Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Ravelli

Showing results (181-190 of 341) with videos related to

Pageof 35
Sort By:
Arthritis and Rheumatism|September 29, 2011
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic featuresNicolino Ruperto, Pierre Quartier, Nico Wulffraat, et al.
Italian Journal of Pediatrics|February 9, 2021
Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of PediatricsMarco Cattalini, Andrea Taddio, Claudia Bracaglia, et al.
Rheumatology (Oxford, England)|March 27, 2010
A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritisGiovanni Filocamo, Benedetta Schiappapietra, Marta Bertamino, et al.
Pediatric Rheumatology Online Journal|September 7, 2022
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trialMarco Burrone, Marta Mazzoni, Roberta Naddei, et al.
The Journal of Rheumatology|March 3, 2011
A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment ReportGiovanni Filocamo, Alessandro Consolaro, Benedetta Schiappapietra, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung diseaseEmanuele Pontali, Stefano Volpi, Giancarlo Antonucci, et al.
The Journal of Rheumatology|April 15, 2026
Systematic literature review informing PReS/CARRA-endorsed recommendations for the treat-to-target strategy in juvenile dermatomyositisAna Isabel Rebollo-Giménez, Talia Baird, Brian M Feldman, et al.
RMD Open|December 10, 2016
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsPiet van Riel, Rieke Alten, Bernard Combe, et al.
RMD Open|February 2, 2024
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity IndexSilvia Rosina, Alessandro Consolaro, Angela Pistorio, et al.
Rheumatology (Oxford, England)|August 23, 2024
Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndromeRoberta Caorsi, Arinna Bertoni, Caterina Matucci-Cerinic, et al.
Pageof 35

Showing results (181-190 of 341) with videos related to

Sort By:
Pageof 35
Arthritis and Rheumatism|September 29, 2011
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic featuresNicolino Ruperto, Pierre Quartier, Nico Wulffraat, et al.
Italian Journal of Pediatrics|February 9, 2021
Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of PediatricsMarco Cattalini, Andrea Taddio, Claudia Bracaglia, et al.
Rheumatology (Oxford, England)|March 27, 2010
A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritisGiovanni Filocamo, Benedetta Schiappapietra, Marta Bertamino, et al.
Pediatric Rheumatology Online Journal|September 7, 2022
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trialMarco Burrone, Marta Mazzoni, Roberta Naddei, et al.
The Journal of Rheumatology|March 3, 2011
A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment ReportGiovanni Filocamo, Alessandro Consolaro, Benedetta Schiappapietra, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung diseaseEmanuele Pontali, Stefano Volpi, Giancarlo Antonucci, et al.
The Journal of Rheumatology|April 15, 2026
Systematic literature review informing PReS/CARRA-endorsed recommendations for the treat-to-target strategy in juvenile dermatomyositisAna Isabel Rebollo-Giménez, Talia Baird, Brian M Feldman, et al.
RMD Open|December 10, 2016
Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsPiet van Riel, Rieke Alten, Bernard Combe, et al.
RMD Open|February 2, 2024
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity IndexSilvia Rosina, Alessandro Consolaro, Angela Pistorio, et al.
Rheumatology (Oxford, England)|August 23, 2024
Long-term efficacy of MAS825, a bispecific anti-IL1β and IL-18 monoclonal antibody, in two patients with systemic JIA and recurrent episodes of macrophage activation syndromeRoberta Caorsi, Arinna Bertoni, Caterina Matucci-Cerinic, et al.
Pageof 35